Wujiapi Powder Veterinary Grade API is a standardised dried extract powder prepared from the dried root bark of Acanthopanax gracilistylus W.W.Smith (Araliaceae), known as Cortex Acanthopanacis. It is supplied under packaging-configuration model identifiers WJ-VET-025 and WJ-VET-001; these denote a 25 kg double-lined fibre drum and a 1 kg aluminium foil pouch, respectively, rather than different potency grades. The manufacturing sequence includes milling of the root bark, solvent extraction, clarification, concentration under reduced pressure, vacuum drying, mechanical milling, and final blending to a controlled particle-size band. The resulting powder is intended for downstream incorporation into tablets, capsules, powders, granules, premixes, oral solutions, and—after additional purification, depyrogenation, and sterile filtration—injectable solutions. Unlike crude Acanthopanax bark powder, the veterinary API grade is controlled for syringin marker content, heavy metals, residual solvents, and microbial burden. Unlike purified syringin single-marker extracts, it retains co-occurring eleutherosides, isofraxidin, and polysaccharide fractions. Those residual botanical matrix constituents change hygroscopicity, dissolution, filtration, and solution clarity; they are therefore critical to dosage-form design and to differentiation from simple recompounded marker blends.

What separates this veterinary API grade from undifferentiated botanical powders?

Crude Acanthopanax bark powder typically carries particle-size distributions above 850 µm, variable total ash, and no documented residual solvent profile. The veterinary API grade is milled to pass 180 µm for premix applications or 75 µm for tablet and capsule work; every lot is released against a certificate of analysis. Release testing includes identity by HPTLC or HPLC against a certified syringin reference, assay of syringin by HPLC-UV, loss on drying, total ash, heavy metals, residual solvents, and microbial enumeration. HPLC system suitability is set at resolution ≥1.5, tailing factor ≤2.0, and replicate injection repeatability ≤2.0% relative standard deviation. Elemental impurities are controlled under ICH Q3D; residual solvents are evaluated under VICH GL18. Microbial enumeration follows Ph. Eur. 2.6.12 and Ph. Eur. 2.6.13 for non-sterile oral preparations. Finished milling and packaging areas are controlled to ISO 14644-1 Class 8 at rest; this supports particulate and microbial control during powder handling but does not confer sterility.

Food-grade Acanthopanax powders, although botanically similar, are not manufactured under veterinary GMP and may fail the microbial or residual solvent criteria required for a dosage-form API. Purified syringin extracts, by contrast, are single-marker products that lack the co-occurring eleutheroside E, isofraxidin, and polysaccharide material retained in Wujiapi Powder Veterinary Grade API. That difference is not cosmetic: it affects dissolution behaviour, hygroscopicity, membrane fouling during sterile filtration, and potential precipitation in acidic injection vehicles. Formulators should not substitute food-grade powder or purified syringin on an equal-mass basis without reformulation and revalidation.

Analytical release criteria and residual solvent control

Because Wujiapi Powder is a plant extract rather than a single chemical entity, release criteria include both marker content and process-related purity attributes. The principal marker, syringin, is a phenolic glycoside that can hydrolyse under acidic conditions; therefore assay is performed under defined extraction and chromatographic conditions. Each certificate of analysis reports the actual syringin value, particle-size distribution, loss on drying, and residual solvent profile. The product is not adjusted to a single arbitrary syringin value by blending isolated marker compounds onto inert carriers; such spiked powders do not reproduce the full extraction matrix and are considered different materials.

Residual solvents are controlled because extraction of Wujiapi root bark may use ethanol or aqueous ethanol. If a process uses a solvent with higher toxicological concern, that solvent must not exceed its concentration limit under VICH GL18. Headspace gas chromatography with flame ionisation detection is the conventional release technique for alcohols and ketones. The API is not supplied as a sterile substance; if a sterile dosage form is required, the final product must be sterilised after formulation.

For tablet and capsule manufacturing, Wujiapi Powder Veterinary Grade API is pre-sieved through a 500 µm safety screen and blended with microcrystalline cellulose, lactose monohydrate, or dibasic calcium phosphate dihydrate. Direct compression is usually feasible only when the API fraction is ≤10% of the core mass. Above 10% and up to approximately 40%, dry granulation by roller compactor or slugging press is preferred because the powder exhibits high hygroscopicity and low bulk density, both of which increase tablet weight variability. The intermediate granulation is assessed by Carr index and Hausner ratio; a Hausner ratio above 1.25 generally indicates the need for additional granulation pressure or glidant. Wet granulation with water can dissolve the syringin fraction and cause marker migration during drying, producing non-uniform distribution within the granule bed. Low-moisture isopropanol granulation reduces this migration but introduces a residual solvent that must be cleared under VICH GL18. Uncoated tablet cores containing the API should be protected from relative humidity above 60%; moisture sorption can raise hardness variability and reduce dissolution. Hardness, friability, and dissolution are dosage-form properties and must be validated on the finished tablet, not inferred from API tests alone.

When roller compaction is used, compactor roll pressure, roll speed, and screen mill speed are set to achieve granules with a D50 between 250 µm and 600 µm; this range is typical for botanical extract tablets and is adjusted according to tablet press feed requirements. If the granule fraction below 150 µm exceeds 30%, recompaction or a second screening step reduces fines and improves weight control. Tablet press tooling should have a low-sticking specification; hygroscopic extract powders can adhere to punch faces when ambient humidity exceeds 55%.

When aqueous injection formulations are prepared from Wujiapi Powder

Injectable manufacturing imposes a different quality boundary. Wujiapi Powder Veterinary Grade API is not supplied sterile, not depyrogenated, and not particle-free at release. A downstream process must therefore include dissolution in Water for Injection, clarification, pre-filtration through 0.45 µm, sterilising filtration through 0.22 µm, and either terminal sterilisation or aseptic filling. The retained polysaccharide fraction can foul 0.22 µm membranes; prefilter capacity calculations and filter integrity testing should be included in the batch record. Syringin is a phenolic glycoside and may undergo acid hydrolysis at low pH or decomposition under prolonged high-temperature sterilisation. Published data for this specific extract configuration are limited, so terminal sterilisation recovery must be verified for each formulation. If syringin recovery falls by more than 5.0% after a proposed sterilisation cycle, aseptic filtration rather than terminal sterilisation becomes the recommended route. Aqueous injection vehicles at pH below 4.0 may develop haze because weakly acidic polyphenolic constituents precipitate under acidic conditions; the precise threshold depends on the final composition. The finished injectable solution must meet the sterility requirements of Ph. Eur. 2.6.1, bacterial endotoxin limits appropriate for the intended route, and particulate matter limits under Ph. Eur. 2.9.19 or Ph. Eur. 2.9.20.

Depyrogenation of a botanical extract solution cannot be assumed by filtration alone; endotoxins may pass through 0.22 µm membranes. A validated endotoxin-reduction step such as heat treatment, acid-base hydrolysis, or affinity membrane treatment may be required, but each option must be tested for syringin stability because heat and pH extremes degrade phenolic glycosides. Filter selection should include a prefilter sized at 0.45 µm and a sterilising-grade filter with a water-wettable membrane; cellulose acetate and polyethersulfone membranes may differ in extract fouling. The final container-closure system must protect the solution from light and oxygen; syringin-containing solutions may discolour on prolonged storage.

In powders, granules, and premixes, the API is incorporated by staged pre-blending rather than direct addition. At inclusion rates below 0.5% of the final feed mass, the fine botanical powder segregates from coarse carriers and can produce assay failures. A pre-blend at 5.0% of the total formula mass with lactose monohydrate, calcium carbonate, or corncob meal is recommended before final mixing. Ribbon blenders or paddle mixers loaded to 60–70% of working volume provide acceptable blend uniformity when the final mix is sampled at 10 locations and tested for syringin. The target relative standard deviation for blend uniformity is ≤5.0%. For oral solutions, the powder is dispersed in purified water, adjusted to pH 5.0–7.0, screened through a 45 µm filter, and preserved with a registered veterinary preservative. Ethanol or propylene glycol may be included as co-solvent if the finished solution complies with VICH GL18 and the target species solvent-tolerance profile. Strong acids, strong bases, and strong oxidising agents should be avoided because acid hydrolysis cleaves the glycosidic linkage of syringin and reduces assay potency. Hard water containing high calcium or magnesium concentrations may form insoluble complexes with polyphenolic constituents and should be avoided in large-volume solutions.

For granules, the API can be incorporated before or after fluid-bed drying of the carrier. If the API is added before drying, inlet air temperature is kept below 60 °C unless stability data support a higher set point. If added after drying, a post-blend step with gentle tumbling reduces segregation. For medicated feed premix applications, prolonged high-shear mixing should be avoided because frictional heat can produce localised temperature increases above 40 °C and accelerate moisture uptake. In oral solutions, the powder is dispersed into the aqueous phase before pH adjustment and before addition of preservatives to avoid localised low-pH hydrolysis. Multi-dose containers require preservative efficacy testing under Ph. Eur. 5.1.3 or an equivalent veterinary standard.

Dosage-form compatibility and substitution boundaries

The product cannot be treated as a direct mass-equivalent substitute for purified syringin, crude bark powder, or synthetic syringin. Substitution boundaries are summarised below; the values cited are processing thresholds or standard designations, not efficacy claims.